1. To test whether almitrine might improve the arterial partial pressure of 0, in patients with chronic obstructive airways disease by improvement of ventilation-perfusion matching, we looked at the interaction between hypoxic and almitrine-induced vasoconstriction in isolated rat lungs perfused with blood at constant flow. Increases in pressure represented increases in resistance. 2. Almitrine, given in increasing doses between challenges with 2% 0,, enhanced hypoxic vasoconstriction at low doses but attenuated it at high doses. 3. Stimulus-response curves to hypoxia of increasing severity gave a sigmoid curve. 4. Almitrine solvent caused small changes in pulmonary artery pressure and shifted the stimulus-response curve slightly in a parallel fashion. 5. Small doses of almitrine enhanced the action of mild to moderate hypoxia, medium doses attenuated moderately severe hypoxia, whereas high doses depressed vasoconstriction due to all degrees of hypoxia. 6. These effects of almitrine on hypoxic vasoconstriction were compared with the effect of solvent by analysis of variance; the results substantiated significant enhancement of hypoxia by small doses and attenuation by large doses. 7. In patients, if similar effects apply, small doses of almitrine would assist ventilation-perfusion matching, but large doses might worsen it. 8. Almitrine-induced vasoconstriction was attenuated by a fall in perfusate temperature in a similar manner to hypoxic vasoconstriction. It was also attenuated by three drugs, chlorpheniramine, propanolol and diethylcarbamazine, all of which also decrease hypoxic vasoconstriction. The similarity between hypoxic and almitrine-induced pulmonary vasoconstriction is further confirmed. tion of ventilation, whereas in the pulmonary circulation it causes locally mediated vasoconstriction [ 1, 21. We found in isolated rat lungs that there was a strong correlation in different subjects between the vasoconstrictor response to hypoxia, which is notoriously variable, and the pulmonary vasoconstrictor response to almitrine. Both responses, unlike those to other pulmonary vasoconstrictor agents, were abolished by the Ca2 + -channel blocker verapamil [2] . However, there are circumstances in which large doses of almitrine, during prior hypoxic constriction, causes dilatation [2-41. There are two possible, not mutually exclusive, explanations: that almitrine sometimes causes secondary release of a dilator substance which we have so far failed to identify, or that almitrine acts at a site where it interferes with the vasoconstrictor response to hypoxia. Furthermore, it is still disputed as to whether the rise in the arterial partial pressure of 0, (Pao,) which takes place during almitrine treatment in patients with chronic obstructive airways disease is due to improvement in ventilation-perfusion matching through enhancement of vasoconstriction in hypoxic areas of lung, or to better ventilation of these regions through a carotid body reflex [5] . Some workers have reported that almitrine enhances hypoxic pulmonary vasoconstriction in animal experiments, whereas others have not detected any such action [6, 7] . Our aim in this study was to investigate interactions between the effects of almitrine and hypoxia on the pulmonary circulation. Secondly, in order to further identify possible similarities between the actions of almitrine and hypoxia, we investigated whether stimuli which selectively modify hypoxic pulmonary vasoconstriction, such as temperature changes and certain relatively specific receptor inhibitors, would also modify the action of almitrine. Our results help to reconcile previously conflicting animal and clinical investigations. A preliminary report has been published [8] .
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anaesthesia, 60 mg/kg intraperitoneally) by a method described previously [9] . Briefly, blood of normal pH and packed cell volume was perfused at constant flow (20 ml/ min) into the pulmonary artery and returned from the left atrium to a reservoir held at 38°C. Lungs were ventilated with air/5% CO, (normoxia) or 2% 0,/5% CO,/balance N, (hypoxia), which caused strong vasoconstriction. In this constant flow preparation increases in pulmonary artery pressure (Ppa) reflect increases in resistance. Ppa was measured with an electromanometer (Druck Ltd) and was displayed on a pen recorder (Advance; Bryan's). The rise in Ppa during hypoxia was measured at the maximum pressure. In most preparations the Ppa then remained stable, but in others there was a decline. The duration of hypoxic tests was variable because the time to maximum Ppa rise varied with the degree of hypoxia and was modified by temperature (and also possibly by almitrine); the interval between tests was at least 5 min, but was continued until a stable baseline pressure was reached. Gas partial pressures in samples of effluent blood were measured immediately with a Corning blood gas analyser. Values for the partial pressure of 0, (Po,) and the partial pressure of CO, did not differ before and after almitrine (see below).
Protocols of experiments
In all experiments several hypoxic tests were performed at the outset until a reproducible response was seen; the first one or two responses were usually less than those seen later.
(1) Dose-response curves to almitrine (0.1, 1.0, 2.0, 5.0,50 and 200 pg) during normoxia (n = 11 rats). Since the effects of large doses were persistent, doses were given in a constant order, small doses first, and were considered cumulative.
(2) Effect of increasing doses of almitrine on repeated hypoxic stimuli (2% O,/5% CO,) (n = 11 rats). The doses given in protocol (l), in the same order, were given between hypoxic challenges.
(3) Effect of different doses of almitrine (1, 2, 5, 50 and 200 pg) on stimulus-response curves to a range of low Po, values. Challenges with 7, 5, 2 and 0% 0, (all + 5% CO,) were given with a normoxic interval between each test; they caused increasing pressor responses. The different 0, concentrations were given in random order. After two complete stimulus-response curves had been obtained (SR1 and SR2), a single dose of almitrine, its solvent or saline in equivalent volume was administered, followed by two further stimulus-response curves (SR3 and SR4) to hypoxia (four tests in all). Eight rats were used for each dose of almitrine and solvent or saline controls.
(4) Effect on the vasoconstriction caused by almitrine and hypoxia of cooling the perfusate from 38 to 15°C and correlation between the two reactions at high and low temperatures for two series of experiments. In experiment 1 ( 1 2 = 9) hypoxia (2% 0,) was tested at the high and low temperatures. A dose of 50 p g of almitrine was then given at the low temperature. Since this dose did not give a repeatable response, the perfusate temperature was raised when the maximal vasoconstriction was achieved at the low temperature ( n = 6). In a second experiment we used 1 pg of almitrine, which gave a repeatable response, although less than that caused by hypoxia. We were therefore able to repeat tests with hypoxia and almitrine at both temperatures. 
Drugs
Almitrine (Servier Laboratories, dissolved in a 50% polyethylene glycol and water mixture), chlorpheniramine (Piriton; Allen and Hanburys), DEC (Sigma), angiotensin I1 (Hypertensin; Ciba), propanolol (Inderal; ICI) were all dissolved in 0.9% (w/v) NaCl.
Statistics
Means and SEMS were calculated. Comparisons of means before and after pharmacological antagonists were made by using paired Student's t-tests. Correlations between variables were made by using least squares linear regression analysis.
To test whether almitrine modified the effect of hypoxia on Ppa in the experiments under protocol (3), we used a method which took into account changes in the response to hypoxia with time, the effect of the solvent, the effect of the rise in baseline pressure with time which we observed with repeated doses of almitrine (protocols 1 and 2), as well as any inter-animal variation. For each level of hypoxia an estimate was obtained from the analysis of variance model of the effect on Ppa of each almitrine dose compared with the effect of solvent alone.
The estimate for a particular hypoxia level and almitrine dose is approximately equal to:
where the average is that of two hypoxic tests in eight rats before or after drug or solvent and APpa is the rise in Ppa. Since there were a few missing values the estimates were not identical with the differences of the averages.
RESULTS
Dose-response to almitrine: protocol I Fig. 1 shows the changes in Ppa when increasing doses of almitrine were given into the pulmonary circulation. The cross-hatched columns show the normoxic Ppa, whereas the superimposed empty columns show the rise in Ppa which followed each dose. After the first dose, the baseline Ppa failed to return to its initial value, although an interval was allowed between doses for it to stabilize. Although in isolated rat lungs there was usually some rise 55. in basal Ppa over several hours [9] , the rise here was greater and was attributable to the continued presence of the drug, known to accumulate in the lung [lo] . The doses should thus be considered cumulative. Note that the solvent, unlike an injection of 0.9% (w/v) NaCI, appeared to cause a small rise in Ppa. Subsequent doses caused vasoconstriction, although with 200 p g of almitrine we observed a fall in all seven rats tested from the greatly increased baseline Ppa, shown by the criss-cross section of the last column. However, 200 pg of almitrine given as a single dose (protocol 3), when Ppa was low, caused a small rise in Ppa.
Effect of increasing doses of almitrine on a constant hypoxic stimulus: protocol 2 The cross-hatched columns show the normoxic Ppa, whereas the superimposed empty columns show the rise in Ppa during the hypoxic test. The dose of almitrine shown below each column was that given before that hypoxic test. Fig. 3(a) shows that the first hypoxic test given after a dose of almitrine was followed by a fall in baseline Ppa below that which had stabilized after the almitrine dose. The baseline pressure and pressor response to hypoxia displayed in Fig. 2 are therefore those of the second hypoxic test after the almitrine dose, as indicated in Fig. 3( a) . The cause of this dilatation after hypoxia which succeeds a dose of almitrine is not yet explained but suggests the release of some relaxant during hypoxia. The baseline I'pa continued to rise, but the combined raised baseline Ppa and the Ppa reached during hypoxia gradually declined. A statistical analysis of the effect of almitrine on hypoxic vasoconstriction was performed on results from further experiments in protocol 3.
Effect of single doses of almitrine on the dose-response to increasing hypoxia: protocol 3
We showed interactions between almitrine and hypoxia in a second way (protocol 3), which proved more informative. Fig. 3(b) shows increased responses to four levels of hypoxia after 1 pg of almitrine. However, the results were complex. In the first place, there was sometimes an increased response to repeat hypoxic stimulus-response curves. Secondly, as in Fig. 1 , there was a gradual increase in baseline Ppa. Thirdly, there was an interaction between the effects of the dose of almitrine and the degree of hypoxia. The results are displayed in Fig. 4 and Table 1 . Fig. 4 shows that the stimulus-response curve to progressively severe hypoxia is approximately sigmoidal. The rise in Ppa is plotted against Po, in effluent blood; Po, ranges for different levels of hypoxia were as follows: 7% O,, 9-1 1 kPa; 5% O,, 7-8.5 kPa; 2% 0,, 3-5 kPa, 0% 0,, 1-2.5 kPa. Fig. 4( a ) shows the four stimulus-response tests; the solvent was given between tests 2 and 3. Responses were increased between tests 1 and 2, still further increased after the solvent and were not changed between tests 3 and 4; the curves were all parallel. [In a similar series of eight rats 0.9% (w/v) NaCl was given between tests 2 and 3 and no effect was recorded.] The other tests, in which doses of almitrine were given between the second and third hypoxic response curves, have been compared with the one in which solvent was given. Figs. 4( b) , 4( c) and 4( d ) show the effects of 1 , s and 200 pg of almitrine, respectively; each of these doses modified the parallel displacement of the curve which followed solvent. After 1 p g and, to a lesser extent, 5 pg of almitrine, the curves became wider apart after moderate hypoxia but after 5 pg of almitrine the separation at severe levels of hypoxia was diminished, while I --. after 200 pg of almitrine the response to all levels of hypoxia was depressed. Table 1 reports the rise in Ppa caused by the least and most severe level of hypoxia (7 and 0% 0,) for all four hypoxic response curves before and after doses of almitrine.
The results of the analysis of variance described in the Methods section are given in Fig. 5 and Table 2 . Fig. 5 shows a three-dimensional plot of the estimate of the difference between almitrine and solvent on the pressor response (APpa) to each level of hypoxia. The estimated A Ppa related to the effect of solvent is plotted vertically, whereas the five almitrine doses and the four hypoxic levels are on the two horizontal axes. There is a change from a positive response (enhancement of hypoxic vasoconstriction) at low doses and moderate hypoxia to a negative response (attenuation) with higher doses and more severe hypoxia. The estimates are made up of three components: (1) the effects on Ppa of the different almitrine doses relative to solvent, (2) the effects of the different degrees of hypoxia and (3) action effects of hypoxia and almitrine dose are much less dramatic but still significant (F,,,,,, = 6.63, P < 0.001). Fig. 5 and Table 1 show that 1 and 2 pg of almitrine enhanced mild hypoxic vasoconstriction but had no effect on more severe hypoxia. High doses of almitrine, 50 and 200 pg, shifted the estimate to negative values, especially with more severe hypoxia. Two micrograms caused inhibition and enhancement to severe and moderate hypoxia, respectively. Five micrograms was the dose after which the eqtimate of the difference between almitrine and solvent switched from positive to negative; there was little effect on moderate hypoxia but attenuation of severe hypoxia. A tenfold dose increase to 50 pg of almitrine caused no greater attenuation of severe hypoxia but now moderate hypoxia was attenuated. The highest dose of almitrine, 200 pg, caused near abolition of hypoxic vasoconstriction at all levels. Table 2 shows the results of the analysis of variance analysis.
Effect of temperature on hypoxic and almitrine-induced vasoconstriction: protocol 4 Table 3 shows the effect of changing the temperature of the perfusate from 38 to 15°C on vasoconstriction by hypoxia and by 50 p g of almitrine (first experiment). The pressor effect of 2% 0, was reduced and developed more slowly. The almitrine produced a small rise in Ppa at the low temperature and a further rise when the temperature was raised. The vasoconstriction in response to angiotensin I1 (0.1-0.5 pg) was not reduced by cooling; in fact, larger responses were recorded at the low temperature, although they developed more slowly. Fig. 6 shows significant relationships between the constrictor effects of hypoxia and almitrine at the high and low temperatures. Results from the second experiment, in which both almitrine and hypoxic tests were repeated at the high, low and then high temperatures, are shown in Fig. 7 ; responses to both stimuli were reversibly reduced at the low temperature.
Effect of pharmacological blocking drugs on hypoxic and almitrine-induced vasoconstriction: protocol 5
In eight rats, 1.0 mg of chlorpheniramine reduced AI'pa caused by hypoxia (2% O?) from 14.5 (SEM 1.5) to 2.8 (SEM 0.5) mmHg (P<0.001, paired t-test) and APpa caused by 1 pg of almitrine from 4.6 (SEM 0.8) to 2.3 (SEM 0.5) mmHg (P<0.005). In 13 rats, 20 mg of DEC reduced the effect of hypoxia from 17.0 (SEM 2.0) to 1.7 (SEM 0.7) mmHg (P<0.001) and that of 1 p g of almitrine from 13.0 (SEM 1.7) to 2.1 (SEM 0.5) mmHg (P<0.001). In eight rats, 2 mg of propranolol reduced APpa to hypoxia from 13.9 (SEM 1.8) to 1.0 (SEM 0.25) mmHg and the effect of the same dose of almitrine from 8.9 (SEM 1.7) to 2. constrictor responses to angiotensin I1 remained. In a second series of tests with DEC, angiotensin I1 was given both before and after the drug; as in the first series, the effects of hypoxia and almitrine were greatly reduced, but the action of angiotensin I1 was little affected. Fig. 8 shows the close correlation between the pressor response to almitrine and hypoxia in all these tests both before and after the three pharmacological inhibitors. Vasoconstrictor responses to angiotensin I1 did not correlate with responses to hypoxia and almitrine. 
DISCUSSION
The experiments designed to display any interaction between hypoxic and almitrine-induced vasoconstriction, which might possibly indicate that they act at a similar site, showed three things. There was enhancement of moderate hypoxic vasoconstriction by small doses of almitrine, continued enhancement of moderate hypoxia by a medium dose with simultaneous attenuation of responses to severe hypoxia and, after the largest dose, attenuation of responses to all levels of hypoxia (Figs. 4  and 5 ) . It is not profitable to speculate on the meaning of these interactions at this time. A simple competitive interaction at a receptor site is not suggested, but the known dilator action of almitrine in large doses might mask such a relationship. The dose represented an approximate concentration in the perfusate of 100,200 and 500 ng/ml and 5 and 20 ,ug/ml. It is not realistic to compare isolated perfused lungs with patients in detail, but our concentrations are in the same range as the blood levels reported during prolonged treatment with almitrine [ 111. The Po, values caused by ventilation with 7 and 5% 0, are closest to those found in hypoxic lung disease, Since submission of this work, a report has been published which also shows that almitrine enhances or depresses hypoxic pulmonary vasoconstriction, according to dose and degree of hypoxia [ 121.
Since almitrine is given with benefit to patients with hypoxic chronic obstructive airway disease, it may be of great importance that it sometimes enhances and sometimes attenuates hypoxic pulmonary vasoconstriction. Pao, is improved in these patients but the argument continues as to whether this is due to small changes in ventilatory pattern or to better ventilation/perfusion matching in the lung, which could also be due to improved ventilation of hypoxic areas [ 5 ] . Better matching could also be due to enhanced hypoxic vasoconstriction and diversion of blood away from such regions. Clearly, the current work, should similar conditions prevail in man, indicates that in a non-homogeneous lung either better or worse matching might result, being dependent on both the tissue levels of almitrine and the severity of hypoxia.
An important point for almitrine therapy is whether it has any effect, given clinically, on Ppa. A large European multi-centre trial [ 111 gave no evidence for increase in this pressure after 1 year of treatment. One small trial, however, did show rises 1131. Tests with almitrine given acutely led only to transient increases in Ppa [14] . In this connection, the dilator effect, observed by several groups as well as ourselves, must be born in mind [2-41; this might counteract any tendency to a rise in Ppa caused by its vasoconstrictor action.
We have shown that pulmonary vasoconstriction induced by almitrine, like hypoxic pulmonary vasoconstriction, is temperature-sensitive, unlike constriction caused by angiotensin 11. This fact, first demonstrated by Nilsen & Hauge [ 151, is one of the most important leads in our search for the still unresolved mechanism of hypoxic pulmonary vasoconstriction which contrasts with its vasodilator action on systemic vessels. Also, both the actions of hypoxia and almitrine in this circulation were selectively abolished by an H ,-receptor blocker, a padrenoceptor antagonist and a drug known to reduce, albeit non-selectively, the vasoconstriction caused by certain leukotrienes. The effect of each of these drugs was, in its time, thought to provide evidence that hypoxic vasoconstriction was caused by release of a specific transmitter. This hypothesis can no longer be held in a simple form, for no single substance explains the phenomenon in all species [16] . Thus in 1968 Hauge [17] and Hauge & Melmon [ 181 found that hypoxic vasoconstriction in the isolated rat lung could be respectively abolished and enhanced by H,-receptor antagonists and histaminase inhibitors. Unfortunately, this elegant work could not be repeated in dogs and cats, and, indeed in the latter, an acatecholamine transmitter seemed a more likely candidate [19, 201 ; moreover, the main action of histamine in this species proved to be an H,-receptormediated vasodilatation [20, 2 11. More recently, other possible transmitters, in particular a leukotriene, have been considered ( [22] and reviewed in [16] ). Again, for no clear reason, propanolol also abolished hypoxic vasoconstriction in the rat [23] . Nevertheless, it is of interest that almitrine-induced pulmonary vasoconstriction is attenuated by three substances which have a relatively specific antagonistic effect on hypoxic vasoconstriction in the rat. Almitrine may prove a useful tool with which to study the mechanism of hypoxic pulmonary vasoconstriction. We have no information as to the cause of the dilator action of almitrine to add to our earlier suggestion that it might be due to release of a vasodilator substance [2] ; a role for endothelial-derived relaxant factor has not been excluded.
